Century Therapeutics (IPSC) Cash & Current Investments (2020 - 2026)

Century Therapeutics (IPSC) has reported Cash & Current Investments for 7 consecutive years, with $134.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Current Investments fell 18.36% year-over-year to $134.8 million; the TTM figure through Mar 2026 stood at $134.8 million (down 18.36% YoY), while the FY2025 annual figure was $168.6 million, down 10.96% from the prior year.
• Cash & Current Investments fell to $134.8 million in Q1 2026 per IPSC's latest filing, from $168.6 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $378.8 million in Q2 2022 and bottomed at $132.7 million in Q3 2025.
• Historically, Cash & Current Investments has averaged $217.3 million across 5 years, with a median of $189.3 million in 2024.
• Annual changes were most pronounced in 2022 — Cash & Current Investments soared 41.56% — and 2023, when it sank 58.71%.
• Century Therapeutics' Cash & Current Investments stood at $315.5 million in 2022, then tumbled by 45.25% to $172.7 million in 2023, then advanced by 9.58% to $189.3 million in 2024, then declined by 10.96% to $168.6 million in 2025, then slipped by 20.02% to $134.8 million in 2026.
• Business Quant data shows IPSC's Cash & Current Investments at $134.8 million in Q1 2026, $168.6 million in Q4 2025, and $132.7 million in Q3 2025.